BioCentury
ARTICLE | Company News

Qiagen, Max Planck Institute for Infection Biology deal

January 16, 2012 8:00 AM UTC

Qiagen and the institute partnered to develop and commercialize a diagnostic test to assess the risk of subjects with latent tuberculosis (TB) developing active TB disease in their lifetime. Both parties will collect, analyze and evaluate data to identify genetic markers. Qiagen will be responsible for assay design, manufacturing and commercializing the product, which is expected to launch in 2013. The institute will offer access to its markers. Terms were not disclosed. ...